Analysts have chosen stocks from pharmaceutical, healthcare and communications spaces for 'buy' recommendations on Thursday.
Centrum Broking Technical and Derivatives Research Vice-President and Head Nilesh Jain, Gemstone Equity Research Founder and Technical Analyst Milan Vaishnav, Nirmal Bang Institution Technical Research Assistant Vice-President Swati Hotkar, and Angel One Technical & Derivatives Senior Research Analyst Osho Krishnan gave their views on the stocks.
Biocon
Centrum Broking's Nilesh Jain recommended a 'buy' on the stock. Target price for the stock is Rs 352, implying an upside of 3.41% from Wednesday's closing price. Stop loss for the stock is Rs 333 apiece.
Out of 19 analysts tracking the company, 11 maintain a 'buy' rating, three recommend a 'hold' and five suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 11.1%.
Krishna Institute Of Medical SciencesÂ
Gemstone Equity Research Founder and Technical Analyst Milan Vaishnav recommended a 'buy' for the stock. Target price for the stock is Rs 710, which implies an upside of 6.98% from Wednesday's closing price. Stop loss for the stock is Rs 620 apiece.
Out of 17 analysts tracking the company, 16 maintain a 'buy' rating, and one recommends a 'hold', according to Bloomberg data. The average 12-month consensus price target implies an upside of 8.7%.
GlaxoSmithKline Pharma
Gemstone Equity Research founder and technical analyst Milan Vaishnav recommended a 'buy' for the stock. Target price for the stock is Rs 3,180, implying an upside of 6.91% from Wednesday's closing price. Stop loss for the stock is Rs 2,900 apiece.
Out of four analysts tracking the company, two maintain a 'buy' rating, one recommends 'hold' and one suggests 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 2.9%.
Tata Communications
Nirmal Bang's Swati Hotkar recommended a 'buy' for the stock. Target price for the stock is Rs 1,720, implying an upside of 2.99% from Wednesday's closing price. Stop loss for the stock is Rs 1,620 apiece.
Out of eight analysts tracking the company, five maintain a 'buy' rating, one recommends a 'hold' and two suggests a 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 8.2%.
Petronet LNGÂ
Angel One's Osho Krishnan recommended a 'buy' for the stock. Target price for the stock is Rs 332, implying an upside of 3.15% from Wednesday's closing price. Stop loss for the stock is Rs 318 apiece.
Out of 35 analysts tracking the company, 12 maintain a 'buy' rating, 11 recommend 'hold' and 12 suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 7.0%.
Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult their own financial or investment adviser before taking any investment decision.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.